logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Life Science
Filter

Life Science

Categories

Sectors

Locations

Exchange

医药保险巨头CVS Health股价飙升的原因是什么?

Impressive Performance Yet Low Stock Price, Can Eli Lilly Usher in a Turning Point with Medicare Coverage?

Mar 31, 2026

Life Science

Pfizer Could Rewrite the GLP-1 Race — but Its 7% Yield Is Flashing a Warning

Viking Therapeutics Approaches Make-or-Break Moment as Key GLP-1 Data Looms

Mar 29, 2026

Life Science

新品+独家合作:Hims & Hers拓展男性健康业务推动股价上涨

Approved Catalyst Fuels Market Movement, Corcept Therapeutics Leads Healthcare Sector This Week

Mar 27, 2026

Life Science

数字医疗行业能否回暖?Hinge Health上市表现引关注

After Surging Over 100% in a Year, Executives Reduce Holdings Amid Adaptive Biotech’s Strong Performance

Mar 27, 2026

Life Science

Oil Surge Puts Canada’s Enbridge-Suncor Combo in the Spotlight

High Volatility, High Reward: Two Biotech Stocks for the Risk-Tolerant Investor

Mar 26, 2026

Life Science

暴跌47%后,联合健康的“护城河”还管用吗?

Under the Spotlight of GLP-1, the Hidden Risks of Eli Lilly’s High Valuation Cannot Be Ignored

Mar 26, 2026

Life Science

美国制药巨头收益和收入超出预期,2023年业绩指引才是重点

After Five Years of Sluggish Performance, Pfizer Finds Renewed Hope in High Dividends and Clinical Data

Mar 25, 2026

Life Science

Vertex Pharmaceuticals在股市表现亮眼

A Pullback or a Buying Opportunity? Analyzing Vertex Pharmaceuticals’ Growth Drivers for the Coming Year

Mar 25, 2026

Life Science

澳洲医疗保健股:这两只股票或具翻倍潜力

Who Will Be the Next Oncology Giant? Axsome and Madrigal Could Overtake by 2026 

Mar 25, 2026

Life Science

Corcept Surges Nearly 20% as FDA Approves Ovarian Cancer Drug Lifyorli

Corcept Surges Nearly 20% as FDA Approves Ovarian Cancer Drug Lifyorli

Mar 25, 2026

Life Science

医疗和AI是两大主题

Tarsus Pharmaceuticals Chief Human Resources Officer Sells Shares, Transaction Highlights Company’s Commercial Momentum

Mar 25, 2026

Life Science

AbbVie Faces ‘Sell-the-News’ Risk in Q2, but Long-Term Conviction Stays Intact

Is Bristol Myers Squibb’s 4.4% Dividend Yield Too Good to Be True?

Mar 24, 2026

Life Science

加拿大两大能源蓝筹股,谁更具投资价值?

Market Turmoil Got You on Edge? These Three Stocks Could Be Your Anchor

Mar 23, 2026

Life Science, Technology

RVMD’s Near-100% Year-To-Date Rally Sparks Valuation Debate: Has the Stock Gotten Too Pricy?

April 10 Looms as Eli Lilly’s Next Big Test: Is the Stock a Buy Before the FDA Verdict?

Mar 22, 2026

Life Science

只需要500美元,就能买入两只无需多虑的医疗股

An Institution Increases Holdings in Sotera Health Against the Trend

Mar 20, 2026

Life Science

AI驱动未来医疗,BioNTech股价应声上涨近4%

Hims & Hers Joins Hands with Former Rival, Hidden Concerns Loom Over the Weight Loss Drug Market Landscape

Mar 18, 2026

Life Science

AbbVie’s $8 Billion Bet Without Breaking a 53-Year Dividend Streak

Two Top Analysts Just Upgraded Edgewise Therapeutics. Here’s Why.

Mar 17, 2026

Life Science

GE医疗股票今日下跌的原因?

How is Pfizer Tackling the “Blockbuster Drug Drought” in the Post-Pandemic Era?

Mar 17, 2026

Life Science

  • ‹‹ Previous
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada